Clover Health Investments Corp. Class A Common Stock (CLOV) Stock Price Today
Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence
Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...
Sutro Biopharma to present at multiple investor conferences in November and December 2026
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
Dimensional Fund Advisors discloses 1.27% stake in Prologis Inc as of Nov 3, 2026
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
Dimensional Fund Advisors discloses 1.78% stake in DCC Energy shares as of Nov 2026
Dimensional Fund Advisors Ltd. has disclosed an interest in 1,516,595 ordinary shares of DCC Energy plc, representing 1.78% of the company's shares as of November 3, 2026. The disclosure follows regulatory requirements under the Irish Takeover Panel ...
Immix Biopharma to present NXC-201 CAR-T trial results for AL amyloidosis at ASH 2026
Immix Biopharma will present interim clinical trial results of its NXC-201 CAR-T therapy for relapsed/refractory AL amyloidosis at the ASH 2026 meeting on December 14. The data comes from the NEXICART-2 trial, the first U.S. trial of CAR-T treatment ...
Rigel to present updated Phase 1b data on R289 and TAVALISSE at ASH 2026 meeting
Rigel Pharmaceuticals will present updated data from its ongoing Phase 1b study of R289, a dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS) at the 2026 ASH Annual Meeting. The data will include...
TuHURA Biosciences to present research on Delta Opioid Receptor's role in immune suppression at ASH 2026.
TuHURA Biosciences announced it will present three posters at the 68th American Society of Hematology Annual Meeting in December 2026, highlighting the Delta Opioid Receptor (DOR) as a key regulator of immune suppressing cells involved in cancer and ...
Autolus updates clinical data on CAR-T therapies for blood cancers at ASH 2026 meeting.
Autolus Therapeutics announced new clinical data presentations at the American Society of Hematology (ASH) Annual Meeting 2026, highlighting progress in their CAR-T therapies for blood cancers. Key updates include deeper measurable residual disease (...
Cullinan Therapeutics to present updated data on CLN-049 and velinotamig at ASH 2026
Cullinan Therapeutics announced that it will present updated clinical data for its T cell engager therapies CLN-049 and velinotamig at the 68th ASH Annual Meeting in December 2026. CLN-049, targeting FLT3 for acute myeloid leukemia (AML) and myelodys...
Actinium unveils promising clinical data on Iomab-ACT for safer conditioning before CAR T-cell and stem cell therapies.
Actinium Pharmaceuticals presented three abstracts at the 68th ASH Annual Meeting highlighting clinical advances with Iomab-ACT, a targeted CD45 radioimmunotherapy. The studies demonstrate Iomab-ACT's potential as a safer conditioning agent before CA...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.